Acetone → 2-[3-Chloro-4-[1-methyl-3-(2-pyridyl)-4,6,7,8-tetrahydropyrazolo[3,4-e][1,4]thiazepin-4-yl]phenyl]propan-2-ol

HRID 1748743Notes

Reaction equation

HRID 1748743 reaction equation
Br[C:2]1[CH:7]=[CH:6][C:5]([CH:8]2[S:14][CH2:13][CH2:12][NH:11][C:10]3[N:15]([CH3:24])[N:16]=[C:17]([C:18]4[CH:23]=[CH:22][CH:21]=[CH:20][N:19]=4)[C:9]2=3)=[C:4]([Cl:25])[CH:3]=1.[CH3:26][C:27]([CH3:29])=[O:28].CO>C1COCC1>[Cl:25][C:4]1[CH:3]=[C:2]([C:27]([OH:28])([CH3:29])[CH3:26])[CH:7]=[CH:6][C:5]=1[CH:8]1[S:14][CH2:13][CH2:12][NH:11][C:10]2[N:15]([CH3:24])[N:16]=[C:17]([C:18]3[CH:23]=[CH:22][CH:21]=[CH:20][N:19]=3)[C:9]1=2

Participants

5

Reactant 3

HCID 180AcetoneHCID 887MethanolHCID 1363484284-(4-Bromo-2-chloro-phenyl)-1-methyl-3-(2-pyridyl)-4,6,7,8-tetrahydropyrazolo[3,4-e][1,4]thiazepine

Product 1

HCID 1362162882-[3-Chloro-4-[1-methyl-3-(2-pyridyl)-4,6,7,8-tetrahydropyrazolo[3,4-e][1,4]thiazepin-4-yl]phenyl]propan-2-olYield 39%

Reagents, catalysts & solvents 1

HCID 8028TetrahydrofuranSolvent2×

Procedure

To a degassed solution of 4-(4-bromo-2-chloro-phenyl)-1-methyl-3-(2-pyridyl)-4,6,7,8-tetrahydropyrazolo[3,4-e][1,4]thiazepine (0.255 g, 0.59 mmol, see Ex.#3 step D) in anhydrous THF (2.5 mL) was added dropwise isopropylmagnesium chloride lithium chloride complex solution (2.25 mL, 1.3 M in THF, 2.93 mmol) at about 0° C. After complete addition, the mixture was stirred at rt for about 4 h, then cooled to about −40° C. and acetone (0.3 mL, 4.1 mmol) was added dropwise. Subsequently, the mixture was warmed to rt, treated with methanol (2 mL) and concentrated in vacuo. The residue was dissolved in ethyl acetate (40 mL), washed with saturated aqueous ammonium chloride (10 mL), dried (MgSO4), filtered and concentrated in vacuo. The resulting residue was purified by column chromatography (SiO2, diethyl ether) to give 2-[3-chloro-4-[1-methyl-3-(2-pyridyl)-4,6,7,8-tetrahydropyrazolo[3,4-e][1,4]thiazepin-4-yl]phenyl]propan-2-ol (0.095 g, 0.23 mmol, 39%) as a white foam: LC-MS (Table 1, Method e) Rt=6.53 min; m/z 415 (M+H)+; 1H-NMR (CDCl3, Bruker 400 MHz) δ 1.52 (3 H, s) 1.53 (3 H, s) 1.69 (1 H, s) 2.71 (1 H, ddd, J=15.0, 5.2, 2.0 Hz) 2.88 (1 H, ddd, J=15.0, 9.3, 2.6 Hz) 3.21-3.29 (1 H, m) 3.57-3.66 (1 H, m) 3.79 (1 H, dd, J=3.8, 5.4 Hz) 3.83 (3 H, s) 6.84 (1 H, s) 7.08 (1 H, ddd, J=7.5, 4.8, 1.1 Hz) 7.20 (1 H, dd, J=8.1, 1.8 Hz) 7.27 (1 H, d, J=8.1 Hz) 7.52 (1 H, d, J=1.8 Hz) 7.59 (1 H, td, J=7.9, 1.8 Hz) 7.73 (1 H, dt, J=7.9, 1.1 Hz) 8.53 (1 H, ddd, J=4.8, 1.8, 1.0 Hz); and 4-(2-chlorophenyl)-1-methyl-3-(2-pyridyl)-4,6,7,8-tetrahydropyrazolo[3,4-e][1,4]thiazepine (0.035 mg, 0.10 mmol, 17%) as a white foam: LC-MS (Table 1, Method e) Rt=7.62 min; m/z 357 (M+H)+; 1H-NMR (CDCl3, Bruker 400 MHz) δ 2.72 (1 H, ddd, J=15.1, 6.1, 2.2 Hz) 2.87 (1 H, ddd, J=15.1, 9.1, 2.5 Hz) 3.23-3.32 (1 H, m) 3.57-3.66 (1 H, m) 3.81 (1 H, br s) 3.84 (3 H, s) 6.82 (1 H, s) 7.05-7.13 (3 H, m) 7.25-7.31 (1 H, m) 7.36-7.42 (1 H, m) 7.59 (1 H, td, J=7.7, 1.5 Hz) 7.72 (1 H, dt, J=8.0, 1.1 Hz) 8.52 (1 H, ddd, J=4.8, 1.5, 0.8 Hz).

Workup

  1. additionAfter complete addition
  2. temperaturecooled to about −40° C.
  3. temperatureSubsequently, the mixture was warmed to rt
  4. concentrationconcentrated in vacuo
  5. dissolutionThe residue was dissolved in ethyl acetate (40 mL)
  6. washwashed with saturated aqueous ammonium chloride (10 mL)
  7. dry with materialdried (MgSO4)
  8. filtrationfiltered
  9. concentrationconcentrated in vacuo
  10. customThe resulting residue was purified by column chromatography (SiO2, diethyl ether)

Sources & evidence

ORD record
ord-8fca4f5bc68942ffa22fa27861c39a73
Source dataset
uspto-grants-2015_10
Patent number
US09150592B2

Reaction notes

Loading…